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Levetiracetam (LEV), an antiepileptic drug (AED) with favorable pharmacokinetic profile, is increasingly 
being used in clinical practice, although information on its metabolism and disposition are still being 
generated. Therefore a simple, robust and fast liquid-liquid extraction (LLE) followed by high-
performance liquid chromatography method is described that could be used for both pharmacokinetic 
and therapeutic drug monitoring (TDM) purposes. Moreover, recovery rates of LEV in plasma were 
compared among LLE, stir bar-sorptive extraction (SBSE), and solid-phase extraction (SPE). Solvent 
extraction with dichloromethane yielded a plasma residue free from usual interferences such as commonly 
co-prescribed AEDs, and recoveries around 90% (LLE), 60% (SPE) and 10% (SBSE). Separation was 
obtained using reverse phase Select B column with ultraviolet detection (235 nm). Mobile phase consisted 
of methanol:sodium acetate buffer 0.125 M pH 4.4 (20:80, v/v). The method was linear over a range of 
2.8-220.0 µg mL-1. The intra- and inter-assay precision and accuracy were studied at three concentrations; 
relative standard deviation was less than 10%. The limit of quantification was 2.8 µg mL-1. This robust 
method was successfully applied to analyze plasma samples from patients with epilepsy and therefore 
might be used for pharmacokinetic and TDM purposes. 
Uniterms: Levetiracetam/pharmacokinetic. High performance liquid chromatography. Antiepileptic 
drugs/therapeutic monitoring. Epilepsy/treatment.
Levetiracetam, fármaco antiepiléptico com perfil farmacocinético favorável, tem sido cada vez mais 
utilizado na prática clínica, embora informações sobre seu metabolismo e disposição cinética ainda estejam 
sendo geradas. Um método simples, robusto e rápido de extração líquido-líquido seguido por análise por 
cromatografia líquida de alta eficiência é aqui descrito para servir tanto a investigações farmacocinéticas 
quanto à monitorização terapêutica. Além disso, as taxas de recuperação do levetiracetam em plasma 
foram comparadas entre a extração líquido-líquido, a extração sortiva em barra de agitação e a extração 
em fase sólida. Extração com o solvente diclorometano resultou em plasma livre de interferentes, tais 
como fármacos antiepilépticos co-prescritos, e apresentou taxas de recuperação em torno de 90% (extração 
líquido-líquido), 60% (extração em fase sólida) e 10% (extração sortiva em barra de agitação). A separação 
foi obtida utilizando-se coluna de fase reversa Select B e detecção ultravioleta (235 nm). A fase móvel foi 
composta por metanol:tampão acetato de sódio 0,125 M pH 4,4 (20:80, v/v). O método mostrou-se linear 
para o intervalo de 2,8 a 220,0 µg mL-1. Precisão intra- e interdias e a exatidão foram avaliadas em três 
concentrações; o desvio padrão relativo foi inferior a 10%. O limite de quantificação foi 2.8 µg mL-1. Este 
método foi aplicado para análise de amostras de plasma de pacientes com epilepsia e, desta forma, pode 
ser utilizado satisfatoriamente tanto para fins de farmacocinética quanto de monitorização terapêutica. 
Unitermos: Levetiracetam/farmacocinética. Cromatografia líquida de alta eficiência. Antiepiléticos/
monitorização terapêutica. Epilepsia/tratamento.
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INTRODUCTION
Levetiracetam (LEV; α-ethyl-2-oxo-1-pyrrolidine 
acetamide; Figure 1) is an antiepileptic drug (AED) 
approved by the Food and Drug Administration to be 
prescribed in polytherapy for management of partial onset 
seizures with or without secondary generalization in adults 
and children with refractory epilepsy, and as monotherapy 
for treatment of partial onset seizures in patients with 
newly diagnosed epilepsy (Mbizvo et al.,2012; Patsalos, 
2004).
Its innovative mechanism of action based on the 
selective binding to a synaptic vesicle protein (SV2A) 
involved in neurotransmitter release (Macdonald; 
Rogawski, 2008) and the favorable pharmacokinetic 
profile makes LEV a promising AED in terms of 
efficacy and tolerability. Levetiracetam presents high 
oral bioavailability, rapid gastrointestinal absorption 
(TMAX = 1 h), linear pharmacokinetics over the therapeutic 
dosages range (1000 – 3000 mg/day), minimal plasma 
protein binding (<10%), and elimination half-life 
estimated at 6 to 8 h in adults. According to Strolin 
Benedetti and colleagues (2003), LEV does not undergo 
chiral interconversion in humans. In contrast to most other 
AEDs, LEV elimination is not significantly dependent on 
the cytochrome P450 enzymatic system; about 66% of 
an oral dose are excreted unchanged in urine, and 24% 
undergo hydrolysis in blood to the inactive metabolite 
ucb L057 (Patsalos, 2004). As a relatively new AED, LEV 
pharmacokinetics is still under investigation, especially 
regarding its disposition and elimination in situations such 
as pregnancy and extremes of ages (Italiano, Perucca, 
2013; Tomson, Landmark, Battino, 2013).
Despite the wide reference range for plasma 
concentration values (12-46 mg/L) and the positive 
pharmacokinetic profile, therapeutic drug monitoring 
(TDM) of LEV is advisable to improve efficacy and safety 
in special situations, namely pregnancy, renal impairment, 
in elderly and pediatric patients, to investigate intoxication, 
therapeutic compliance or overdose (Krasowski, 2010; 
Patsalos et al., 2008; Tomson et al., 2007). Several 
chromatographic methods have been published for 
quantification of LEV concentrations in biological fluids 
such as saliva and plasma (or serum) for TDM and in 
urine for pharmacokinetic aims. They include different 
subtypes of liquid chromatography with various detection 
systems (Contin et al., 2008; Grim et al., 2003; Guo et al., 
2007; Jain et al., 2006; Juenke et al., 2006; Kuhn, Knabbe, 
2013; Lancelin et al., 2007; Martens-Lobenhoffer, Bode-
Boger, 2005; Matar, 2008; Pucci et al., 2004; Rao et al., 
2004; Ratnaraj, Doheny, Patsalos, 1996; Shibata et al., 
2012), gas chromatography (Isoherranen et al., 2000; 
Mecarelli et al., 2007) and microemulsion electrokinetic 
chromatography (Ivanova et al., 2003). An analytical non-
chromatographic method, capillary electrophoresis, is also 
described (Shihabi, Oles, Hinsdale, 2003). Because of the 
advantages of high-performance liquid chromatography 
(HPLC) over other analytical methods, namely in terms 
of versatility and simplicity of sample preparation, as well 
as wide linearity range in detectors, relative low cost and 
widespread use in laboratories, it has become the gold 
standard method for TDM not only for LEV, but also for 
all other AEDs monitored (Queiroz et al., 2008).
Different sample pretreatment techniques have been 
described for LEV analysis, with recoveries ranging from 
12% to 99%, according to the method and reagents. Solid-
phase extractions (SPE) of LEV performed with different 
polymeric sorbents such as C18 and hydrophilic-lipophilic 
balanced copolymer are described in the literature 
(Isoherranen et al., 2000; Ivanova et al., 2003; Mecarelli 
et al., 2007; Pucci et al., 2004; Vermeij, Edelbroek, 1994). 
Protein precipitation is considered a simple, inexpensive 
and suitable pretreatment procedure especially for drugs 
minimally bound to plasma proteins. Preparation usually 
consists of adding organic solvents such as methanol or 
acetonitrile; formation of insoluble salts through addition 
of zinc sulphate or perchloric acid is also possible (Contin 
et al., 2008; Martens-Lobenhoffer, Bode-Boger, 2005; 
Pucci et al., 2004). Although dilutions can affect the 
sensitivity of the method, this procedure is considered 
a positive pretreatment method because LEV is not 
significantly bound to plasma proteins (Pucci et al., 2004). 
Few publications are based on liquid-liquid 
extraction (LLE) for LEV (Ratnaraj; Doheny; Patsalos, 
1996). Although time-consuming and highly dependent 
on organic solvents, LLE is a feasible and inexpensive 
method used both for TDM and pharmacokinetics 
purposes (Chollet, 2002; Isoherranen et al., 2003; Patsalos 
et al., 2006). 
More recently, stir bar-sorptive extraction (SBSE) 
has been evaluated for the enrichment of organic solutes 
FIGURE 1 - Chemical structures of levetiracetam and ucb 17025 
(internal standard).
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from biological fluids. It is a non-exhaustive sample 
preparation technique based on the partitioning coefficient 
of the solutes between the non-polar silicone phase made 
of polydimethylsiloxane (PDMS) and the aqueous phase. 
Although this process is still under deeper investigation, 
it is becoming more popular for different matrices and 
analytes (David, Sandra, 2007), including therapeutic 
drugs (Queiroz et al., 2008).
Considering that analytical procedures allowing 
rapid and robust quantifications of LEV concentrations 
in biologic fluids are of great interest both for TDM 
and pharmacokinetic applications, this work aimed to 
present a study of a reliable analytical method based 
on comparisons of recovery rates from LLE, SBSE and 
SPE cleanup procedures followed by HPLC analysis for 
determination of LEV concentrations in plasma samples. 
Noteworthy, as the purpose is centered in the comparison 
of the above-mentioned extraction methods, validation 
aspects are shown as pertinent. 
MATERIAL AND METHODS
The plasma samples used in the present study 
were obtained from patients with epilepsy attending 
the Ribeirão Preto Clinical Hospital. Procedures were 
performed under written consent and approved by the local 
Ethics Committee (Approval nº 11133/2008).
Instrumentation and reagents
The analyses were performed on an HPLC system 
consisting of a Shimadzu LC 10AD pump (Japan), 
a Shimadzu SPD 10A ultraviolet (UV) detector, a 
Chromatopac C-R8A integrator (Shimadzu, Columbia, 
MD, USA) and a Rheodyne injector with a 20 μL loop. 
Supleco® cartridges (C18, 3 mL) were used for SPE. 
The procedure was carried out on a vacuum apparatus 
(Marconi, Brazil). For SBSE, the commercial stir bar 
Twister® (10 mm long glass-encapsulated magnetic stir 
bar externally coated with 22 μg of PDMS) was obtained 
from Gerstel (Gerstel GmbH, Mulheim Ruhr, Germany).
Acetonitrile and dichloromethane (analytical grade) 
were purchased from Merck KGaA, Darmstadt, Germany. 
Methanol HPLC grade was obtained from J.T. Baker® 
HPLC, Mallinckrodt Baker Inc., USA. Sodium acetate 
anhydrous, sodium hydroxide, di-Natriumtetraborate-
10-hydrat and glacial acetic acid 100% anhydrous (for 
analysis) were obtained from Merck KGaA, Darmstadt, 
Germany. Deionized water was obtained using a Milli-Q 
water processing system (Millipore, São Paulo, Brazil). 
Levetiracetam and the internal standard (IS) ucb 17025 
(α,2,2-trimethyl-5-oxo-1-pyrrolidine acetamide; Figure 1) 
were a kind donation from Prof. Emilio Perucca’s lab. 
Methods
Calibration curve
Stock solutions of LEV in water (0.22 mg mL-1) 
and of IS in methanol (260.0 μmol L-1) were prepared and 
stored at -20 °C. These solutions were stable for at least five 
months. Routine daily calibration curves were prepared 
for each analytical batch by adding LEV and IS working 
solutions to drug-free plasma in order to produce LEV 
concentrations of 7.13, 11.88, 19.8, 33.0 and 55.0 µg mL-1. 
Analytical conditions
Chromatographic separation was achieved 
isocratically, at room temperature, using an analytical 
column (250x4 mm i.d.) with precolumn (4x4 mm) 
packed with LiChrospher 60 RP-select B, 5 μm particle 
size (Merck®). Mobile phase consisted of a mixture of 
methanol and sodium acetate buffer 0.125 M, pH 4.4 
(20:80, v/v) daily prepared and degassed. The mobile 
phase was delivered into the HPLC system at a flow-rate 
of 1.0 mL min-1. The UV detector was set at 235 nm.
Sample preparation for SPE
The SPE cartridge was conditioned with 2 mL 
of methanol followed by 2 mL of water. A mixture of 
100 mL of plasma with 25 mL of IS and 3 mL of borate 
buffer (0.1 M, pH 9.0) was mixed in a vortex-type shaker 
for 1 min, and loaded into the cartridges which were 
previously dried under low vacuum at room temperature. 
The cartridges were then washed with 5 mL of water and 
dried under vacuum for 5 min. Elution was performed 
with 2 mL of dichloromethane under low vacuum at room 
temperature. The eluate was transferred into conic tubes 
to be evaporated under constant airflow. The dry residue 
was reconstituted in 50 mL of the mobile phase and, after 
vortexing for 10 s, 20 mL were injected into the HPLC 
system. 
Sample preparation for SBSE
Prior to first use, the stir bar was placed into a vial 
containing acetonitrile and conditioned for 24 h. A mixture 
of 100 mL of plasma sample with 3 mL of borate buffer (0.1 
M, pH 9.0) and 25 mL of IS was vortexed for 1 min at room 
temperature. The stir bar was immersed into the sample 
and the extraction was performed under a magnetic stirring 
rate of 1200 rpm for 30 min at 50 ºC. For desorption, the 
stir bar was firstly removed with tweezers, carefully dried 
in clean tissue and put in a glass tube containing 2 mL of 
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dichloromethane, ensuring total immersion. Desorption 
was performed under a magnetic stirring rate of 1200 rpm 
for 30 min at 50 ºC. After the desorption step, the stir bar 
was removed by means of a magnetic rod and the solvent 
was evaporated to dryness at room temperature under 
airflow. The dry residue was reconstituted in 50 mL of 
mobile phase and 20 µL were injected into the HPLC 
system after shaking for 10 s in a vortex-type shaker. 
After each the successive extraction the used stir bar was 
cleaned in methanol for 30 min at 50 °C (under a magnetic 
stirring rate of 1200 rpm), followed by a drying step using 
a lint-free tissue.
Sample preparation for LLE
Liquid-liquid extraction was based on that previously 
proposed by Ratnaraj, Doheny and Patsalos (1996) with 
minor modifications herein described. Twenty five 
microliters of IS were added to 25 µL of NaOH 5 M, 
2 mL of dichloromethane and 100 µL of plasma. The 
mixture was shaken in a vortex-type shaker for 1 min 
and then centrifuged at 1800 rpm for 5 min. The organic 
phase was transferred to conic tubes and evaporated under 
constant airflow at room temperature. The dry residue was 
reconstituted in 50 mL of mobile phase and, after shaking 
for 10 s in a vortex-type shaker, 20 mL were injected into 
the HPLC system.
HPLC method validation
Recovery rates were determined at the five different 
concentrations from the calibration curve. Levetiracetam 
was extracted in triplicate from human blank plasma 
according to each method proposed above and the UV-
peak heights were compared to the direct injection of 
standard solutions of equal concentrations. 
In order to obtain intra- and inter-assay precisions, 
aliquots (n=10 and n=5, respectively) of blank plasma 
containing LEV and IS at three different concentrations 
were analyzed. The inter-assay precision was determined 
based on analyses of blank plasma containing LEV and 
IS solutions at the same three concentrations for five 
consecutive days. Accuracy was checked using three 
concentrations within the linear range of the procedure. 
The accuracy values accepted showed variations of less 
than 15%.
Linearity was determined by analyzing drug-free 
plasma samples (n=3) containing LEV and IS solutions at 
concentrations from 2.85 to 220.0 μg mL-1, a range wide 
enough to cover the routine calibration curve (from 7.13 
to 55.0 µg mL-1). The concentration range was estimated 
based on the regression curve (y=ax + b) and correlation 
coefficient (R2). 
The limit of quantification (LOQ) was determined 
by analyzing drug-free plasma samples spiked with 
decreasing concentrations of LEV standard solution. The 
LOQ was considered the lowest concentration quantified 
with a relative standard deviation (RSD) of less than 10%, 
obtained from five determinations. 
RESULTS
Table I displays the concentration range to which 
linearity was determined, the regression curve and 
correlation coefficient referred to the range, and the 
comparison of LEV recovery rates from the different 
extraction procedures evaluated.
Validation parameters for LLE are shown in Table 
II. Figure 2 displays representative chromatograms from 
the validated method applied to clinical samples. 
DISCUSSION
Three different sample preparation procedures 
were tested and compared for LEV extraction from 
human plasma. Recovery rates were assumed as the 
most important figure of merit in comparing the cleanup 
procedures, i.e., methods with low recovery rates (<80%) 
TABLE I - Comparison of LEV recovery rates from the different extraction procedures
LEV conc. 
(μg.mL-1) Linear regression; R
2
Limit of 
quantification 
(μg.mL-1)
Absolute recoveries
Evaluated conc. 
(μg.mL-1)
Results (%)
LLE SPE SBSE
2.85 – 220.0 y = 0.0245x + 0.1842 
0.991
2.85 7.1 90.2 60.7 11.6
11.9 92.5 61.9 11.0
19.8 91.1 59.7 12.2
33.0 89.7 60.2 10.1
55.0 87.1 60.4 10.0
LEV: levetiracetam; LLE: liquid-liquid extraction; SBSE: stir bar-sorptive extraction; SPE: solid phase extraction. 
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TABLE II - Intra- and inter-assay precision and accuracy data for LEV according to the validated method
LEV conc. 
(μg.mL-1)
Precision Intra-assay RSD (%) 
n=10
Precision Inter-assay RSD (%) 
n=5 Accuracy error (%)
13.0 5.4 5.0 4.9
15.0 6.0 5.0 9.6
30.0 7.0 6.6 3.8
RSD: relative standard deviation; LEV: levetiracetam.
FIGURE 2 - Chromatograms from the validated method. (A): drug-free plasma sample (blank); (B): plasma spiked with LEV and 
IS to the final LEV concentration of 55 μg mL-1; (C): clinical sample from an adult patient with epilepsy on lamotrigine chronic 
treatment (200 mg/day) obtained 9 hours after the ingestion of a LEV single dose (1000 mg); (D): clinical sample from an adult 
patient with epilepsy on carbamazepine chronic treatment (600 mg/day) obtained 1 hour after the ingestion of a LEV single dose 
(1000 mg). IS: internal standard; LEV: levetiracetam.
were considered unsatisfactory for our aims and eventually 
were not validated. Although recovery rate was the most 
important parameter in determining the validity of the 
method, other aspects such as complexity of execution, 
time-consumption and amounts of organic solvents 
required were also balanced in order to discuss the most 
suitable method for TDM and pharmacokinetic aims. 
The stationary phase (C18) here selected for SPE 
analyses is considered a reasonable choice according 
to Isoherranen and colleagues (2000), Ivanova and 
colleagues (2003), Vermeij and Edelbroek ( 1994) and 
Chollet ( 2002), although Pucci and co-workers (2004) 
argue against the reproducibility of the results obtained 
from this sorbent among different batches. Considering 
the high hydrophilic characteristic of LEV, our present 
elution performed with dichloromethane can possibly 
explain the low recovery rates found (Table I) and to what 
is reported elsewhere (Isoherranen et al., 2000; Pucci et 
al., 2004; Vermeij,Edelbroek, 1994; Zufia et al., 2010). 
Among the organic solvents commonly used in SPE, 
dichloromethane has a polarity index of 3.4, while it is 
6.6 for methanol. This is suggestive that mixtures with 
higher polarity indexes such as acetonitrile and methanol 
(Zufia et al., 2010) or methanol and water (Vermeij, 
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Edelbroek, 1994) would extract LEV from stationary 
phase efficiently. Despite the main advantages of SPE, 
namely the purification and enrichment of analytes from 
complex matrices and the use of low amounts of organic 
solvents, it is an expensive and time-consuming procedure, 
not reliable especially for analyses of large amounts of 
samples as in pharmacokinetic studies and routine TDM 
analyses. Furthermore, in our specific case, the low 
recovery rates found would not be suitable for neither 
pharmacokinetics nor for TDM purposes.
To our knowledge, no publication in the literature 
has tried to extract LEV from any matrix using SBSE. 
This extraction method has proven to be an interesting and 
environmentally friendly alternative to LLE considering 
its insignificant organic solvent consumption and higher 
limits of detection (David, Sandra, 2007). However, the 
even lower recovery rates obtained from SBSE (Table I) 
make this procedure a non-suitable cleanup method. As 
bars with different coatings other than PDMS are released, 
this method could be optimized for extracting LEV from 
human plasma. 
Liquid-liquid extraction modified from Ratnaraj and 
co-workers (Ratnaraj; Doheny; Patsalos, 1996) proved to 
be the most satisfactory of the evaluated methods. Due to 
the high recovery rates (Table I), validation parameters 
were established only for LLE, as illustrated in Table II. 
The LOQ found was 2.85 μg mL-1. Calibration curves 
were linear in the range of 2.85-220.0 μg mL-1, with 
R2 = 0.991. Linear regression equation was defined 
as y=0.0245x+0.1842. Accuracy and intra- and inter-
assay precision were studied at three concentrations, as 
summarized in Table II. The RSD were less than 10%. 
The small amount of biological matrix needed 
(100 μL) makes this a suitable method even for children. 
The pretreatment steps presented here are free of 
toxic solvents such as petroleum ether and chloroform 
(Isoherranen et al., 2003) and provided results without 
any interference from drugs normally used with no 
prescription. Accordingly, there were no interfering peaks 
related to endogenous nor exogenous compounds, as can 
be observed on the chromatograms (Figure 2), where drug-
free human plasma, spiked human plasma and clinical 
samples from patients with epilepsy show the ability of 
the method to quantify LEV unequivocally. 
Several mobile phases were tested and the proposed 
(methanol:sodium acetate buffer 0.125 M, pH 4.4, 20:80 
v/v) was the simplest that yielded satisfactory separation 
in a acceptable run time with retention times of 6.5 min 
for LEV and 8.0 min for IS (Figure 2). The complete 
elution was obtained in less than 20 min through isocratic 
mode, in contrast to Vermeij and Edelbroek ( 1994) and 
Martens-Lobenhoffer and Bode-Boger ( 2005) who 
performed gradient runs for their analyses. Remarkably, 
the isocratic mode of elution is still the preferred choice 
when compared to gradient elution, possibly because of 
improvements in column efficiencies as well as issues 
related to equilibration time, throughput, ease of use and 
availability of suitable pumps (Chollet, 2002). 
Solvent extraction with NaOH and dichloromethane, 
the mobile phase described, and detection at 235 nm 
showed high sensitivity and resolution for detection of 
LEV in human plasma. Different wavelengths between 
205 and 240 nm were tested. Considering that real clinical 
samples can be difficult to yield chromatographic peak 
separations because of comedications and endogenous 
interferences, a high wavelength set at 235 nm showed to 
be the best for selectivity instead of the UV detection at 
205 nm (very unspecific) described elsewhere (Contin et 
al., 2008; Martens-Lobenhoffer, Bode-Boger, 2005; Pucci 
et al., 2004; Zufia et al., 2010). 
The polytherapies frequently prescribed to 
approximately one third of all patients with epilepsy 
who do not achieve satisfactory seizure control with 
currently available AEDs in monotherapy (Sander, 2003) 
often include drugs such as carbamazepine, phenytoin, 
phenobarbital and benzodiazepines. Figures 2C and 2D 
illustrate the selectivity of the method on two plasma 
sample chromatograms, as they show the absence of 
interfering peaks of lamotrigine (2C) and carbamazepine 
(2D), two commonly used AEDs, in LEV and IS analyses. 
Chromatograms shown in Figure 2C and 2D were obtained 
from adult patients with epilepsy chronically treated with 
lamotrigine 200 mg/day and carbamazepine 600 mg/day, 
respectively, after receiving a single oral dose of LEV 
1000 mg. Although no reference range has been definitely 
established for LEV, clinical studies published using adult 
patients with epilepsy show LEV plasma concentrations 
mostly ranging from 12 to 46 µg mL-1 (Patsalos et al., 
2008), values fully in accordance with our proposed 
quantification range.
CONCLUSIONS
This paper presents a simple, robust and fast 
method for determination of LEV in human plasma 
using reverse-phase HPLC combined with UV detection. 
The method is compatible with pharmacokinetic studies 
and TDM. Based on figures of merit results, the LLE 
procedure proved to be adequate to LEV analyses from 
sub-therapeutic to toxic levels. The assay was successfully 
applied to the analysis of real samples once it could be 
considered selective, especially for patients with epilepsy 
Stir bar-sorptive extraction, solid phase extraction and liquid-liquid extraction for levetiracetam determination 399
in chronic treatment with AEDs other than LEV. Taken into 
account that the core of the present study is the methods 
comparison essentially based on their recovery rates, LLE 
was considered a shorter step, precise and an inexpensive 
sample preparation method to be routinely used instead of 
the other methods evaluated. 
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